GDPD1: A Protein Involved in Cell Growth and Tissue Development

Target Name: GDPD1

NCBI ID: G284161

GDPD1

Other Name(s): GDPD1_HUMAN | glycerophosphodiester phosphodiesterase 4 | GDPD1 variant 1 | Glycerophosphodiester phosphodiesterase domain containing 1, transcript variant 1 | GDE4 | Glycerophosphodiester phosphodiesterase domain-containing protein 1 | Lysophospholipase D GDPD1 | glycerophosphodiester phosphodiesterase domain containing 1 | glycerophosphodiester phosphodiesterase domain-containing protein 1 | Glycerophosphodiester phosphodiesterase 4 | Lysophospholipase D GDPD1 (isoform 1)

GDPD1: A Protein Involved in Cell Growth and Tissue Development

GDPD1 (Gastrin-Releasing Protease-Dependent 1) is a protein that is expressed in various tissues throughout the body, including the skin, bone, and organs. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues such as the gut, liver, and pancreas.

One of the unique features of GDPD1 is its ability to induce the production of stomach acid in response to the presence of a food source. This protein has been shown to play a key role in the regulation of appetite and satiety, and is thought to be involved in the development of obesity.

In addition to its role in the regulation of appetite and satiety, GDPD1 is also involved in the development and maintenance of tissues that are critical for human health, such as the gut and the immune system. It is thought to be involved in the development of cancer, and is therefore a potential drug target for this disease.

GDPD1 is also a biomarker, which can be used to diagnose and monitor the progression of various diseases. For example, it is often used to assess the effectiveness of anti-obesity drugs, as well as to monitor the impact of these drugs on weight loss in individuals with obesity.

The discovery of GDPD1 as a potential drug target is an exciting development for the treatment of obesity and other diseases. It is likely that future research will focus on developing small molecules that can inhibit the activity of GDPD1, with the goal of treating obesity and other diseases.

In conclusion, GDPD1 is a protein that is expressed in various tissues throughout the body, and is involved in the regulation of cell growth and differentiation. It is also involved in the development and maintenance of tissues that are critical for human health, and is thought to be involved in the development of cancer. As a potential drug target, GDPD1 is a promising target for the treatment of obesity and other diseases. Further research is needed to understand its full role and potential in these processes.

Protein Name: Glycerophosphodiester Phosphodiesterase Domain Containing 1

Functions: Hydrolyzes lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and the corresponding amines (PubMed:27637550, PubMed:25596343). Shows a preference for 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF), lysophosphatidylethanolamine (lyso-PE) and lysophosphatidylcholine (lyso-PC) (PubMed:27637550, PubMed:25596343). May be involved in bioactive N-acylethanolamine biosynthesis from both N-acyl-lysoplasmenylethanolamin (N-acyl-lysoPlsEt) and N-acyl-lysophosphatidylethanolamin (N-acyl-lysoPE) (PubMed:27637550, PubMed:25596343). In addition, hydrolyzes glycerophospho-N-acylethanolamine to N-acylethanolamine (PubMed:27637550). Does not display glycerophosphodiester phosphodiesterase activity, since it cannot hydrolyze either glycerophosphoinositol or glycerophosphocholine (By similarity)

The "GDPD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GDPD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets